Exalenz Plunges Most in Five Months as Investment Talks End
By David Wainer -
2012-04-30T13:01:40Z
Exalenz Bioscience Ltd. (EXEN) plunged the most in five months in Tel Aviv trading after the maker of breath-testing systems ended talks to receive an investment from a private fund.
Exalenz tumbled 12 percent, the biggest intraday slump since Nov. 29, to 0.3520 shekel as of 3:58 p.m. in Tel Aviv, trimming its market value to 47 million shekels ($13 million).
To contact the reporter on this story: David Wainer in Tel Aviv at dwainer3@bloomberg.net
To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net
Sponsored Link
Rate this Page
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.